|
1
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Five-year outcomes with pembrolizumab versus chemotherapy
for metastatic non-small-cell lung cancer with PD-L1 tumor
proportion score ≥ 50. J Clin Oncol. 39:2339–2349. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wakelee H, Liberman M, Kato T, Tsuboi M,
Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, et al:
Perioperative pembrolizumab for early-stage non-small-cell lung
cancer. N Engl J Med. 389:491–503. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tabuchi T, Ito Y, Ioka A, Miyashiro I and
Tsukuma H: Incidence of metachronous second primary cancers in
Osaka, Japan: Update of analyses using population-based cancer
registry data. Cancer Sci. 103:1111–1120. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Travis LB: The epidemiology of second
primary cancers. Cancer Epidemiol Biomarkers Prev. 15:2020–2026.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Montefusco E, Petti MC, Alimena G,
Latagliata R, Celesti F, Capria S, Amadori S, Avvisati G and
Mandelli F: Etoposide, intermediate-dose cytarabine and carboplatin
(VAC): A combination therapy for the blastic phase of chronic
myelogenous leukemia. Ann Oncol. 8:175–179. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kantarjian H, O'Brien S, Jabbour E,
Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F,
Faderl S, Kadia T, et al: Improved survival in chronic myeloid
leukemia since the introduction of imatinib therapy: A
single-institution historical experience. Blood. 119:1981–1987.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wylie AA, Schoepfer J, Jahnke W,
Cowan-Jacob SW, Loo A, Furet P, Marzinzik AL, Pelle X, Donovan J,
Zhu W, et al: The allosteric inhibitor ABL001 enables dual
targeting of BCR-ABL1. Nature. 543:733–737. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Koo SM, Kim KU, Kim YK and Uh ST:
Therapy-related myeloid leukemia during erlotinib treatment in a
non-small cell lung cancer patient: A case report. World J Clin
Cases. 9:7205–7211. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
McNerney ME, Godley LA and Le Beau MM:
Therapy-related myeloid neoplasms: When genetics and environment
collide. Nat Rev Cancer. 17:513–527. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim HB, Park SG, Hong R, Kang SH and Na
YS: Acute myelomonocytic leukemia during pembrolizumab treatment
for non-small cell lung cancer: A case report. World J Clin Cases.
8:2833–2840. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW:
The 2016 revision to the World Health Organization classification
of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hasford J, Baccarani M, Hoffmann V,
Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele
G, Lindoerfer D, et al: Predicting complete cytogenetic response
and subsequent progression-free survival in 2060 patients with CML
on imatinib treatment: The EUTOS score. Blood. 118:686–692. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ren M, Hong M, Liu G, Wang H, Patel V,
Biddinger P, Silva J, Cowell J and Hao Z: Novel FGFR inhibitor
ponatinib suppresses the growth of non-small cell lung cancer cells
overexpressing FGFR1. Oncol Rep. 29:2181–2190. 2013. View Article : Google Scholar : PubMed/NCBI
|
